Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort
Multicenter cohort analysis reveals late relapse risks in myelofibrosis patients after transplant, highlighting the role of molecular profiling and salvage therapy.
Key Points
To assess long-term outcomes and relapse risk in patients with myelofibrosis following allogeneic hematopoietic stem cell transplantation.
Clinical data collection from 234 patients with primary and secondary myelofibrosis undergoing alloHCT
Longitudinal chimerism assessment and molecular profiling using next-generation sequencing
Kaplan-Meier method for survival estimates and Cox regression for multivariate analysis.
15.4% cumulative incidence of relapse at 1 year and 27.1% at 5 years post-transplant
Mutations in TP53 linked to poor outcomes
Salvage therapy resulted in 77.8% achieving second remission.